Results for this period
Full year1 July 2025 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
There was no business revenue because the Company was unable to secure a partnering company, while research and development expenses increased by ¥237 million due to clinical trial costs, including preparations for the next-phase clinical trial of CBP501, and spending related to next-generation projects. Selling, general and administrative expenses also increased by ¥11 million.
Disclosure of significant events and other matters is provided. Although circumstances exist that raise significant doubt, the Company has determined that there are no significant concerns regarding cash management for the 12 months following the end of the fiscal year and that no material uncertainty exists regarding the going concern assumption. No related note is applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 July 2025 to 30 June 2026 |
| Operating profit | -1,358 million yen |
| Ordinary income | -1,307 million yen |
| Profit attributable to owners of the parent | -1,308 million yen |
| Net income per share | ¥(66.42) |
| Equity ratio | End of the current fiscal period 90.2% / End of previous period 95.4% |
| Total assets | 1,776 million yen |
| Net assets | 1,642 million yen |
| Cash flows from operating activities | -1,424 million yen |
| Cash and cash equivalents at end of period | 1,445 million yen |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not provided because the impact of partnering agreements and other factors, as well as the progress of the CBP501 clinical trial, is difficult to forecast reasonably. |
| Annual Dividend Forecast | 0.00 yen and sen → 0.00 yen and sen（0.0%） |
| Regional sales | Not applicable (there was no revenue from external customers) |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | No applicable matters |
| Disclosure regarding the going concern assumption | Disclosure of significant events and other matters is provided. Although circumstances exist that raise significant doubt, the Company has determined that there are no significant concerns regarding cash management for the 12 months following the end of the fiscal year and that no material uncertainty exists regarding the going concern assumption. No related note is applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For securities analysts and institutional investors |
| Issued Shares at Period-End | 19,713,655 Shares |
| Treasury Shares at Period-End | 10,598 Shares |
| Factors Behind Changes in Business Performance | There was no business revenue because the Company was unable to secure a partnering company, while research and development expenses increased by ¥237 million due to clinical trial costs, including preparations for the next-phase clinical trial of CBP501, and spending related to next-generation projects. Selling, general and administrative expenses also increased by ¥11 million. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There was no business revenue because the Company was unable to secure a partnering company, while research and development expenses increased by ¥237 million year on year due to clinical trial costs, including preparations for the next-phase clinical trial of CBP501, and spending related to next-generation projects. Selling, general and administrative expenses also increased by ¥11 million.